Observational studyDrug design, development and therapy2026
Amphotericin B Colloidal Dispersion Is Effective and Safe for the Treatment of Invasive Aspergillosis in Chinese Patients with Hematologic Disease: A Multicenter, Prospective, Observational, Real-World Study.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Invasive aspergillosis (IA) causes significant morbidity and mortality in hematologic patients. This study aimed to evaluate the efficacy and safety profile of amphotericin B colloidal dispersion (ABCD) for IA in this high-risk population. Patients and Methods: This multicenter, prospective, observational study enrolled hematologic patients with IA. Eligible patients received ABCD for up to 28 days or until investigator-assessed clinical response or intolerance. The primary outcome was clinical response rate, and the secondary outcome was 28-day all-cause mortality following the last dose of ABCD. Safety was assessed based on the incidence and severity of adverse events (AEs). Results: From January 2022 to May 2024, a total of 65 patients were included. The median duration of ABCD treatment was 19 days (range, 1 to 28 days). Across all patients in the full analysis set (FAS), the clinical response rate was 64.62% (42/65). Whereas, in the per-protocol set (PPS), which comprised patients who completed at least 7 days of therapy, the response rate increased to 80.39% (41/51). Notably, only two patients died (3.08%) within 28 days following the last dose of ABCD. Furthermore, exploratory subgroup analysis revealed higher response rates in patients with possible IA, Eastern Cooperative Oncology Group performance status score (ECOG) score of 0-2, baseline body temperature below 38°C, and acute lymphoblastic leukemia. Treatment-related AEs were predominantly grade 1-2, demonstrating a favorable safety profile. The absence of grade 3/4 elevated creatinine events indicated the low nephrotoxicity of ABCD. Univariate and multivariate analyses of clinical response identified longer duration of ABCD treatment as the only independent predictor of clinical response. Nevertheless, the study predominantly included patients with possible IA and employed an observational single-arm design, and the findings should therefore be interpreted cautiously and may not be directly generalizable to populations with microbiologically confirmed IA. Conclusion: Our findings support ABCD as an effective and well-tolerated treatment in hematologic patients with IA, thus providing a reliable therapeutic option for managing IA in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.